Psychedelic Finance

Helping investors discover, understand, and stay up-to-date on opportunities within the Psychedelic industry. Inquiries: [email protected]

[Psychedelic Finance @Psych_Fin]

Welcome to Psychedelic Finance.

We exist to help bridge the gap between the exciting world of psychedelic medicine and the companies being built around it.

If you'd like to see our more detailed research on the industry, you can join the community here:

https://t.co/XSxLwPFI8N

[Psychedelic Finance @Psych_Fin]

$CMPS

[The Tape @TheTape_TNM]

Breaking: $CMPS completes its FDA application for COMP360 psilocybin for treatment-resistant depression, targeting a first-half 2027 launch subject to approval and rescheduling.

[Psychedelic Finance @Psych_Fin]

$PBM

[The Tape @TheTape_TNM]

Breaking: $PBM has completed an additional $2.6 million cash investment in psychedelic ingredient developer PsyLabs, raising its stake from approximately 41.13% to 43.37%.

[Psychedelic Finance @Psych_Fin]

$CMND

[The Tape @TheTape_TNM]

Breaking: $CMND submits FDA recommendations seeking faster approval pathways and potential at-home use of psychedelic-derived treatments that avoid hallucinations.

[Psychedelic Finance @Psych_Fin]

$PBM

[The Tape @TheTape_TNM]

Breaking: $PBM’s Texas unit signs a binding term sheet for exclusive U.S. rights to develop and distribute PsyLabs’ ibogaine, with up to $1.3 million in milestones; a final deal is due by November 30.

[Psychedelic Finance @Psych_Fin]

$PBM

[The Tape @TheTape_TNM]

Breaking: $PBM agrees to invest up to $5 million in PsyLabs, including $2.4 million committed, plus a roughly $9 million share swap to support a potential Texas trial of ibogaine for opioid use disorder.

[Psychedelic Finance @Psych_Fin]

$ENVB

[The Tape @TheTape_TNM]

Breaking: $ENVB receives its third U.S. patent allowance for EVM401, covering non-hallucinogenic mescaline-derived drug candidates for potential PTSD and other mental health treatments.

[Psychedelic Finance @Psych_Fin]

$PBM

[The Tape @TheTape_TNM]

Breaking: $PBM forms Texas Ibogaine Research Corp. to coordinate U.S. drug supply, regulatory work and potential clinical development.

[Psychedelic Finance @Psych_Fin]

$DFTX

[The Tape @TheTape_TNM]

Breaking: $DFTX receives FDA Breakthrough Therapy designation for DT120 in major depression after a positive Phase 3 trial showed durable improvement through Week 12.

[The Tape @TheTape_TNM]

Breaking: $DFTX receives FDA Breakthrough Therapy designation for DT120 in major depression after a positive Phase 3 trial showed durable improvement through Week 12.

[The Tape @TheTape_TNM]

Breaking: $HELP completes enrollment in its Phase 3 HLP003 depression trial with topline data expected in Q4, while Q1 net loss widens to $47.8 million and cash stands at $166.4 million.

[The New Money @thenewmoney]

Breaking: Compass Pathways has partnered with the U.S. Department of Veterans Affairs for a new psilocybin study.

$CMPS $ATAI $LLY

https://t.co/anNDSHApYH

[The Tape @TheTape_TNM]

Breaking: $CMPS partners with the U.S. Department of Veterans Affairs on a five-site trial of COMP360 psilocybin for veterans with treatment-resistant depression, including those with PTSD.

[Psychedelic Finance @Psych_Fin]

@TheTape_TNM Congrats @Helus_Pharma @insidepharma

[The Tape @TheTape_TNM]

Breaking: Shares of psychedelic drug discovery company $HELP have surged +50% over the past month.

[Psychedelic Finance @Psych_Fin]

@TheTape_TNM Well done @Helus_Pharma

[The Tape @TheTape_TNM]

Breaking: $HELP completes 223-patient Phase 3 enrollment for depression drug HLP003 ahead of schedule, with topline data due Q4 2026.

[The New Money @thenewmoney]

Eli Lilly has entered into a new deal to acquire AtaiBeckley for up to $3.5 billion in the drugmaker’s first ever psychedelic drug discovery acquisition.

$ATAI $LLY @C_Angermayer

https://t.co/fbgmy93t1C

[The New Money @thenewmoney]

Definium Therapeutics has just completed a massive new capital raise.

And they are aiming to use it to bring their most advanced psychedelic derived drug into commercialization.

$DFTX

https://t.co/cnGltUfXLv

[The Tape @TheTape_TNM]

Breaking: $CMND completes treatment of all 24 participants across four cohorts in Part A of its FDA-regulated Phase I/II CMND-100 trial for alcohol use disorder and will review the data before advancing to the next stage.

[The New Money @thenewmoney]

A publicly traded company on the Nasdaq is shipping psilocybin to the United Kingdom. But, why?

$OPTH

https://t.co/GamoFvBHRR